Drug intelligence / Profile preview

SEMA3A mAb

Development stage: Preclinical
Lead developer: SemaThera
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravitreal, Intravenous

Overview

SEMA3A mAb is a monoclonal antibody developed by SemaThera that targets Semaphorin-3A (SEMA3A). SEMA3A is a secreted protein known to play a role in axonal guidance and has been implicated in pathological angiogenesis and vascular permeability in the retina and kidneys. By antagonizing SEMA3A, this antibody aims to treat conditions like diabetic nephropathy and serves as a potential companion diagnostic in ophthalmology. It is currently in the preclinical stage of development.

Other names: anti-SEMA3A monoclonal antibodyanti-SEMA-3A monoclonal antibodyanti-SEMA 3A monoclonal antibodyanti-SEMA3A antibodyanti-SEMA-3A antibodyanti-SEMA 3A antibody

Targets

SEMA3A (Semaphorin-3A)

Beyond the preview

Go deeper on SEMA3A mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SEMA3A mAb.

Explore the full profile